Fujirebio Diagnostics Announces FDA Clearance of Lumipulse® G CA19-9-N Assay
MALVERN, Pa., Dec. 17, 2019 /PRNewswire-PRWeb/ -- Fujirebio Diagnostics, Inc., a consolidated subsidiary of Miraca Holdings Inc., has received U.S. Food and Drug Administration (FDA) clearance of the company's Lumipulse G1200 CA19-9-N assay for testing on its LUMIPULSE G1200 immunoassay platform.